Package Leaflet: Information for the Patient
Zydelig 150 mg film-coated tablets
idelalisib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Zydelig is a cancer medicine that contains the active substance idelalisib. It works by blocking the effects of an enzyme involved in the multiplication and survival of certain white blood cells called lymphocytes. As this enzyme is overactive in certain cancerous white blood cells, blocking it will eliminate cancer cells and reduce their number.
Zydelig can be used to treat two different types of cancer in adults:
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia(CLL) is a cancer of a type of white blood cell called B lymphocytes. In this disease, lymphocytes multiply too quickly and live too long, so there are too many circulating in the blood.
In CLL, treatment with Zydelig is used in combination with another medicine (rituximab) in patients who have certain high-risk factors or in patients whose cancer has come back after at least one previous treatment.
Follicular lymphoma
Follicular lymphoma(FL) is a cancer of a type of white blood cell called B lymphocytes. In follicular lymphoma, B lymphocytes multiply too quickly and live too long, so there are too many in the lymph nodes. In FL, Zydelig is used alone in patients whose cancer has not responded to two previous cancer treatments.
Do not take Zydelig
→ Consult your doctorif this applies to you.
Warnings and precautions
Talk to your doctor before you start taking Zydelig. Tell your doctor:
Severe and fatal infections have occurred in patients treated with Zydelig. You will need to take an additional medicine that your doctor will provide while you are taking Zydelig to prevent a type of infection. Your doctor will monitor you for signs of infection. Tell your doctor immediately if you become ill (especially if you have a fever, cough, or difficulty breathing) while taking Zydelig.
Tell your doctor immediately if you notice or someone else notices in you: memory loss, confusion, difficulty walking, or loss of vision – these may be due to a rare but serious brain infection that can be fatal (progressive multifocal leukoencephalopathy or PML).
You will need to have regular blood testsbefore and during treatment with Zydelig. This is to check that you do not have an infection, that your liver is working properly, and that your blood counts are normal. If necessary, your doctor may decide to stop treatment for a while, before starting it again at the same dose or at a lower dose. Your doctor may also decide to stop treatment with Zydelig permanently.
Zydelig may cause severe diarrhoea. Tell your doctor immediately at the first sign of diarrhoea.
Zydelig may cause inflammation of the lungs. Tell your doctor immediately:
Severe blistering skin conditions have been reported in some people treated with Zydelig while also taking other medicines that are known to cause these potentially fatal conditions. Blistering may also affect the lining of the mouth, genitals, and/or eyes. Skin peeling may cause serious infection. Tell your doctor immediately:
Laboratory tests may show an increase in white blood cells (called "lymphocytes") in the blood in the first few weeks of treatment. This is expected and may last for a few months, and usually does not mean that your blood cancer is getting worse. Your doctor will review your blood counts before treatment or during treatment with Zydelig and in rare cases may need to give you another medicine. Talk to your doctor about what the test results mean.
Children and adolescents
Do not give this medicine to children and adolescents under 18 years old because it has not been studied in this age group.
Other medicines and Zydelig
Zydelig must not be used with other medicines unless your doctor has told you it is safe to do so.
Tell your doctor if you are taking, have recently taken, or might take any other medicines.This is extremely important because using more than one medicine at the same time can increase or decrease their effects.
Taking Zydelig with certain medicines may make them not work properly or make their side effects worse. In particular, tell your doctor if you are taking any of the following:
Zydelig may be prescribed in combination with other medicines for the treatment of CLL. It is very important that you also read the package leaflets supplied with these medicines.
Ask your doctor if you have any questions about your medicines.
Pregnancy and breast-feeding
Do not breast-feed while taking Zydelig.If you are currently breast-feeding, consult your doctor before starting treatment. It is not known if the active substance of Zydelig passes into breast milk.
Driving and using machines
It is unlikely that Zydelig will affect your ability to drive or use machines.
Take this medicine exactly as your doctor has told you.
If you are not sure, ask your doctor again.
The recommended doseis 150 mg by mouth twice a day. However, your doctor may reduce this dose to 100 mg twice a day if you experience certain side effects.
Zydelig can be taken with or without food.
Swallow the tablet whole.Do not chew or crush the tablet. Tell your doctor if you have problems swallowing the tablets.
If you take more Zydelig than you should
If you accidentally take a larger dose of Zydelig than recommended, you may have a higher risk of side effects with this medicine (see section 4, Possible side effects).
Contact your doctor or the nearest emergency department immediately for advice. Take the bottle and this leaflet with you so that you can easily describe what you have taken.
If you forget to take Zydelig
Try to avoid missing any dose of Zydelig. If you miss a dose and it has been less than 6 hours, take the missed dose immediately. Then, take the next dose as usual. If you miss a dose and it has been more than 6 hours, wait and take the next dose at the usual time.
Do not stop taking Zydelig
Do not stop taking this medicine unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects could be serious.
STOP taking Zydelig and seek medical help immediately if you have any of the following symptoms:
Other side effects
Very common side effects
(may affect more than 1 in 10 people)
Blood tests may also show:
Common side effects
(may affect up to 1 in 10 people)
Blood tests may also show:
Reporting of side effects
If you experience any side effects, talk to your doctor, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}. The expiry date is the last day of the month shown.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Zydelig composition
Microcrystalline cellulose, hydroxypropylcellulose (E463), sodium croscarmellose, sodium starch glycolate, magnesium stearate.
Film coating:
Polyvinyl alcohol (E1203), macrogol 3350 (E1521), titanium dioxide (E171), talc (E553B), red iron oxide (E172).
Appearance and packaging of the product
The film-coated tablets are pink, oval-shaped tablets, with "GSI" engraved on one side and "150" on the other.
The following pack size is available: outer carton with 1 plastic bottle of 60 film-coated tablets.
Marketing authorization holder
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Manufacturer
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
Belgium Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 | Lithuania Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
Bulgaria Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Luxembourg Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 |
Czech Republic Gilead Sciences s.r.o. Tel: + 420 910 871 986 | Hungary Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Denmark Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 | Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Germany Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0 | Netherlands Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98 |
Estonia Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | Norway Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Greece Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: + 30 210 8930 100 | Austria Gilead Sciences GesmbH Tel: + 43 1 260 830 |
Spain Gilead Sciences, S.L. Tel: + 34 91 378 98 30 | Poland Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
France Gilead Sciences Tel: + 33 (0) 1 46 09 41 00 | Portugal Gilead Sciences, Lda. Tel: + 351 21 7928790 |
Croatia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Romania Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 999 | Slovenia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Iceland Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 | Slovakia Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 210 |
Italy Gilead Sciences S.r.l. Tel: + 39 02 439201 | Finland Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Cyprus Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: + 30 210 8930 100 | Sweden Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Latvia Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | United Kingdom Gilead Sciences Ltd Tel: + 44 (0) 8000 113700 |
Date of last revision of this leaflet
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.